Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network
Authors' conclusion
GLP-1RA significantly improved BMI, HbA1c and triglycerides in a large majority of patients with FPLD. Larger and prospective controlled studies are warranted for identification of predictive factors and safety.
Study context
- Population
- Patients with familial partial lipodystrophy (FPLD) in the French lipodystrophy reference network who initiated GLP-1 RA (2008–2024); 89.4% women, median age 48 years, body mass index (BMI) 26.0 kg/m², HbA1c 8.3%; 50% insulin-treated
- Participants
- 76 patients
- Exposure
- Before vs after GLP-1 RA initiation
- FPLD2n = 57
- FPLD3n = 4
- FPLD4n = 5
- FPLD1n = 10
- Outcome
- BMI, HbA1c and triglycerides after GLP-1 RA
- Follow-up
- One year (12 ± 6 months)
Methodological detailsreal-life setting, national reference network, uncontrolled
- Real-life setting
- National reference network
- Uncontrolled
Main finding
As reported in the abstract
- BMI decreased from 26.0 kg/m² (IQR 23.9-29.5) to 25.6 kg/m² (IQR 22.7-29.1); p < 0.001
- HbA1c decreased from 8.3% (IQR 7.5-9.3) to 7.3% (IQR 6.6-8.3); p < 0.001
- TG decreased from 2.31 mmol/L (IQR 1.62-3.88) to 1.97 mmol/L (IQR 1.5-3.2); p < 0.01
- Median (IQR)
- No significant changes in other antidiabetic and lipid-lowering drugs
Observational data: associations, not effects.
Further findings
Gamma-glutamyl-transferase and alanine-aminotransferase · one year
- Significantly decreased
HbA1c, BMI and TG long term · latest follow-up (≥18 months)
- Effects persisted in the long term
Safety
Adverse events · during follow-up
- Acute pancreatitis, associated with severe hypertriglyceridemia in a non-observant patient
- 1 case
- Gastrointestinal symptoms
- 34%
- GLP-1 RA withdrawal due to gastrointestinal symptoms
- 6 patients
Original publication
Safety and effectiveness in an uncontrolled setting of glucagon‐like‐peptide‐1 receptor agonists in patients with familial partial lipodystrophy: Real‐life experience from a national reference network. Diabetes Obes Metab. Published 20 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →